Unlike last year's billion dollar approvals, Avastin (bevacizumab) and Erbitux (cetuximab), no biotech blockbusters were launched in 2005 and none appear to be on the horizon. Almost half of the biologics license applications pending at the US Food and Drug Administration (FDA) are for supplementary indications (for drugs already on the market). Certain biotech therapies are among the fastest growing drug market segments (mAbs sales grew by 52% in 2005); five of the 20 best-selling drugs are large molecules. Biotech increasingly dominates the pipeline (44% of all discovery stage candidates) and has a growing share of drug applications (about one in ten of filings).
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech drug market steadily expands. Nat Biotechnol 23, 1466 (2005). https://doi.org/10.1038/nbt1205-1466
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1205-1466
This article is cited by
-
Biopharmaceutical benchmarks 2006
Nature Biotechnology (2006)
